Aptorum Group announces funding to support pending merger with DiamiR Biosciences

Reuters
2025/10/10
Aptorum Group announces funding to support pending merger with DiamiR Biosciences

Aptorum Group Limited has entered into agreements for a registered direct offering of 1,000,000 Class A ordinary shares at $2.00 per share, raising gross proceeds of $2 million. In a concurrent private placement, the company will also issue unregistered warrants to purchase up to 2,000,000 Class A ordinary shares at an exercise price of $2.00 per share, which could generate up to an additional $4 million if fully exercised. The net proceeds from the offering are intended to fund expenses related to the previously announced merger agreement between Aptorum and DiamiR Biosciences Corp., as well as for general working capital for both companies while the merger process continues. The merger is still subject to certain conditions, including approval by Aptorum's shareholders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptorum Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9543656-en) on October 10, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10